



TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/645,930
		Filing Date	August 22, 2003
		First Named Inventor	Helen Strekalova et al.
		Art Unit	1645
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	9	Attorney Docket Number	020187.0231PTUS

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Todd Buck, Reg No. 48,574	
Signature		
Date	January 8, 2004	

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Helen Strekalova et al. Confirmation No.: 8279
Application No. : 10/645,930 Group Art Unit: 1645
Filed : August 22, 2003 Examiner: Not yet assigned
For : METHODS FOR DIAGNOSING DEMENTIA-RELATED
NEUROLOGICAL DISORDERS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 (b)(3)

Honorable Commissioner of Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.56, Applicants direct the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08a. Submission of these citations and the enclosed references is, in no way, an admission that these cited referenced constitute prior art against the subject matter claimed in the above-captioned application. Copies of the references are being submitted herewith.

Applicant respectfully requests that each of the cited references be considered during the prosecution, and that the cited references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

It is believed that this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Thus, under 37 C.F.R. 1.97(b)(3), no certification or fee is required.

Please credit or debit Deposit Account No. 50-2228 as needed to ensure consideration of the disclosed information.

Respectfully submitted,

Date: January, 8, 2004

By: Todd B. Buck

Todd B. Buck
Registration No. 48,574

Patton Boggs, LLP
8484 Westpark Drive
9th Floor
McLean, VA 22102
Telephone (703) 744-7983
Facsimile (703) 744-8091

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Complete if Known

Application Number	10/645.930
--------------------	------------

Filing Date	August 22, 2003
-------------	-----------------

First Named Inventor	Helen Strekalova
----------------------	------------------

Art Unit	1645
----------	------

Examiner Name	Not Yet Assigned
---------------	------------------

Attorney Docket Number	020187.0231PTUS
------------------------	-----------------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]


Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Subsidiary Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	10/645,930
Filing Date	August 22, 2003
First Named Inventor	Helen Strekalova
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	020187.0231PTUS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ANDREASEN N, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol, Mar 2001; 58:373-379.	
		BARBEAU D, et al. Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains. Proc Natl Acad Sci U S A March 1995; 92:2785-2789.	
		COTMAN CW, et al. Cell adhesion molecules in neural plasticity and pathology: similar mechanisms, distinct organizations? Prog Neurobiol 1998; 55:659-669.	
		CREMER H, et al. Long-term but not short-term plasticity at mossy fiber synapses is impaired in neural cell adhesion molecule-deficient mice. Proc Natl Acad Sci U S A Oct. 1998; 95:13242-13247.	
		CROSSIN KL, and Krushel LA. Cellular signaling by neural cell adhesion molecules of the immunoglobulin superfamily. Dev Dyn. June 2000; 218:260-79.	
		ECKHARDT M, et al. Mice deficient in the polysialyltransferase ST8SialV/PST-1 allow discrimination of the roles of neural cell adhesion molecule protein and polysialic acid in neural development and synaptic plasticity. J Neurosci, July 2000; 5234-5244.	
		FIELDS RD, and Itoh K. Neural cell adhesion molecules in activity-dependent development and synaptic plasticity. Trends Neurosci 1996; 19:473-480.	
		FOLSTEIN MF, et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. Nov. 1975; 12:189-198.	
		FRANSEN E, et al. CRASH syndrome: clinical spectrum of corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraparesis and hydrocephalus due to mutations in one single gene, L1. Eur J Hum Genet. Sept.-Oct. 1995; 3:273-284.	
		FROSCH M, et al. NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc Natl Acad Sci U S A, Feb. 1985; 82:1194-1198.	
		GALASKO D. Cerebrospinal fluid opens a window on Alzheimer disease. Arch Neurol. June 1999; 56:655-656.	


Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/645,930
Filing Date	August 22, 2003
First Named Inventor	Helen Strekalova
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	020187.0231PTUS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GARLIND A, et al. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res 1999; 826:112-116.	
		GIBB WR, and Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry, June 1988; 51:745-752.	
		GILMAN S, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163:94-98.	
		GROWDON JH. Biomarkers of Alzheimer disease. Arch Neurol, March 1999; 56:281-283.	
		HAMPEL et al. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol, April 2001; 49:545-546	
		HARLOW E, and Lane D. Antibodies: a Laboratory Manual, cold Spring Harbor Laboratory Publications, New York, 1998.	
		HASPEL J, et al. Critical and optimal Ig domains for promotion of neurite outgrowth by L1/Ng-CAM. J Neurobiol, Feb. 2000; 42:287-302.	
		HOCK C, et al. Increased CSF levels of nerve growth factor in patients with Alzheimer's disease. Neurology, May 2000; 54:2009-2011.	
		JOUE T et al. X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene. Nat Genet, July 1994; 7:402-407.	
		KALUS I, et al. The Proprotein Convertase PC5A and a Metalloprotease Are Involved in the Proteolytic Processing of the Neural Adhesion Molecule L1. J Biol Chem. Mar. 2003; 278:10381-10388.	
		KAMIGUCHI H, et al. Role of L1 in neural development: what the knockouts tell us. Mol Cell Neurosci 1998; 12:48-55.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substantive Patent 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	10/645,930
Filing Date	August 22, 2003
First Named Inventor	Helen Strekalova
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	020187.0231PTUS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LAMMICH S, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A, Mar. 1999; 96:3922-3927.	
		LEWIS LL, et al. Molecular And Functional Analysis of Human Natural Killer Cell-Associated Neural Cell Adhesion Molecule (N-Cam/CD56). J. Immuno. June 1991; 12: (146) 4421-4426.	
		MASSARO AR and Tonalì P. Cerebrospinal fluid markers in multiple sclerosis: an overview. Multiple Sclerosis 1998; 4: 1-4.	
		MCDONALD WI, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol, July 2001; 50:121-127.	
		MCKEITH IG. Dementia with Lewy bodies. Br J Psychiatry, Feb. 2002; 180:144-147.	
		MCKHANN G, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, July 1984; 34:939-944.	
		MILLER PD, et al. Regional distribution of neural cell adhesion molecule (N-CAM) and L1 in human and rodent hippocampus. J Comp Neurol, June 1993; 327:341-349	
		MURASE S, and Schuman EM. The role of cell adhesion molecules in synaptic plasticity and memory. Curr Opin Cell Biol 1999; 11:549-553.	
		POLTORAK M, et al. Increased neural cell adhesion molecule in the CSF of patients with mood disorder. J Neurochem 1996; 66:1532-1538.	
		POLTORAK M, et al. Disturbances in cell recognition molecules (N-CAM and L1 antigen) in the CSF of patients with schizophrenia. Exp Neurol, Feb. 1995; 131:266-272.	
		PURCELL AE, et al. Assessment of neural cell adhesion molecule (NCAM) in autistic serum and postmortem brain. J Autism Dev Disord. April 2001; 31:183-194.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

5

Complete if Known

Application Number	10/645,930
Filing Date	August 22, 2003
First Named Inventor	Helen Strekalova
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	020187.0231PTUS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ROMAN GC, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, Feb. 1993; 43:250-260.	
		RONN LC, et al. The neural cell adhesion molecule in synaptic plasticity and ageing. Int J Dev Neurosci 2000; 18:193-199.	
		ROSENTHAL A, et al. Aberrant splicing of neural cell adhesion molecule L1 mRNA in a family with X-linked hydrocephalus. Nat Genet 1992; 2:107-112.	
		RUNKER AE, et al. The C264Y missense mutation in the extracellular domain of L1 impairs protein trafficking in vitro and in vivo. J Neurosci, Jan. 2003; 23:277-286.	
		SCHACHNER M. Neural recognition molecules and synaptic plasticity. Curr Opin Cell Biol 1997; 9:627-634.	
		SUGAWA M, et al. Enhancement of neurite outgrowth by the soluble form of human L1 (neural cell adhesion molecule). Neuroreport, Sep. 1997; 8:3157-3162.	
		THELIN J, et al. Heat nociception is severely reduced in a mutant mouse deficient for the L1 adhesion molecule. Brain Res 2003; 965:75-82.	
		THOMAIDOU D, et al. Soluble forms of NCAM and F3 neuronal cell adhesion molecules promote Schwann cell migration: identification of protein tyrosine phosphatases zeta/beta as the putative F3 receptors on Schwann cells. J Neurochem 2001; 78:767-778.	
		VUTSKITS L, et al. PSA-NCAM modulates BDNF-dependent survival and differentiation of cortical neurons. Eur J Neurosci, April 2001; 13:1391-1402.	
		WHEAL HV, et al. Molecular mechanisms that underlie structural and functional changes at the postsynaptic membrane during synaptic plasticity. Prog Neurobiol 1998; 55:611-640.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.